5 alpha-Androstane-3 alpha, 17 beta-diol Glucuronide (3 alpha-Diol G) LIA

$230.00

The Eagle Biosciences 5α-Androstane-3α, 17β-Diol Glucuroninde (3α-Diol G) LIA is for the direct quantitative determination of 5α-androstane-3α, 17β-diol glucuronide (3α-Diol G) in human serum by a chemiluminescence immunoassay (LIA). The Eagle Biosciences 5α-Androstane-3α, 17β-Diol Glucuroninde (3α-Diol G) LIA for research use only and not to be used in diagnostic procedures.

SKU: 5AA31-L01 Categories: , , ,

5 alpha-Androstane-3 alpha, 17 beta-diol Glucuronide (3 alpha-Diol G) LIA

For Research Use Only

Size: 1×96 wells
Sensitivity: 0.1 ng/mL
Dynamic Range: 0.25–50 ng/mL
Incubation Time: 60 minutes
Sample Type: Serum
Sample Size: 50 μL

Controls Included

Additional Information

Assay Background


5α-androstane-3α, 17β-diol glucuronide is a C19 steroid and is either abbreviated as 3α-Diol G, 5α diol G or simply, α diol G. It is produced mainly as a metabolite of testosterone and dihydrotestosterone (DHT). It is largely produced in target peripheral tissues such as the skin, especially around hair follicles. The stimulation by large amounts of 3α-Diol G leads to excessive hair formation, notably where hair is not normally present in women. In recent years the interest in the measurement of this steroid has increased among clinical investigators studying women suffering from idiopathic hirsutism. Among the steroids known to be precursors for 3α-Diol G are dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), dihydrotestosterone (DHT), androstenedione and testosterone. Only 3α-Diol G has been shown to increase with hirsutism and decrease with treatment. This correlation has also been demonstrated in patients with polycystic ovarian syndrome (PCO). 3 α-Diol G determinations have therefore proved to be a useful indicator in a variety of ways including monitoring the progress of treatment of idiopathic hirsutism and women with PCO. Furthermore, diabetic patients (both men and women) under cyclosporine A therapy have shown increased 3 α-Diol G levels, a s ide effect resulting in the appearance of hair in previously hairless areas.

Assay Principle


The principle of the following chemiluminescence immunoassay (LIA) test follows the typical competitive binding scenario. Competition occurs between an unlabelled antigen (present in standards, controls and patient samples) and an enzyme-labelled antigen (conjugate) for a limited number of antibody binding sites on the microplate. The washing and decanting procedures remove unbound materials. After the washing step, the luminescence substrate solution is added. The relative luminescence units (RLUs) are measured on a microtiter plate luminometer. The RLU values are inversely proportional to the concentration of 3α-Diol G in the sample. A set of calibrators are used to plot a standard curve from which the amount of 3α-diol G in patient samples and controls can be directly read.

Manual

Product Manual